Revenue Breakdown
Composition ()
No data
Revenue Streams
Azenta Inc (AZTA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sample management solutions, accounting for 54.0% of total sales, equivalent to $77.71M. Another important revenue stream is Multiomics. Understanding this composition is critical for investors evaluating how AZTA navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Azenta Inc maintains a gross margin of 42.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 1.12%, while the net margin is 32.33%. These profitability ratios, combined with a Return on Equity (ROE) of 1.40%, provide a clear picture of how effectively AZTA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, AZTA competes directly with industry leaders such as MD and AVAH. With a market capitalization of $1.75B, it holds a significant position in the sector. When comparing efficiency, AZTA's gross margin of 42.76% stands against MD's 100.00% and AVAH's 32.19%. Such benchmarking helps identify whether Azenta Inc is trading at a premium or discount relative to its financial performance.
